Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 42.98M | 56.29M | 68.18M | 56.69M | 53.03M | 38.60M |
Gross Profit | 39.04M | 51.53M | 61.20M | 52.43M | 46.91M | 35.25M |
EBITDA | -22.89M | 21.51M | 23.28M | 17.79M | 19.45M | 15.96M |
Net Income | 37.05M | 40.90M | 20.58M | 14.32M | 17.22M | 14.01M |
Balance Sheet | ||||||
Total Assets | 522.60M | 239.83M | 78.06M | 62.69M | 50.67M | 34.64M |
Cash, Cash Equivalents and Short-Term Investments | 13.48M | 14.92M | 57.20M | 43.09M | 37.32M | 22.08M |
Total Debt | 96.28M | 70.00K | 160.00K | 245.00K | 325.00K | 332.00K |
Total Liabilities | 139.19M | 9.08M | 6.27M | 7.02M | 5.13M | 4.85M |
Stockholders Equity | 383.41M | 230.75M | 71.80M | 55.68M | 45.55M | 29.79M |
Cash Flow | ||||||
Free Cash Flow | -117.31M | 24.36M | 20.50M | 15.30M | 15.23M | 14.36M |
Operating Cash Flow | 12.46M | 24.41M | 21.33M | 17.46M | 16.06M | 15.42M |
Investing Cash Flow | -366.41M | -189.98M | 18.40M | -26.84M | -825.00K | -1.31M |
Financing Cash Flow | 360.10M | 117.19M | -5.41M | -4.94M | 13.00K | 230.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $300.05M | 21.62 | 7.64% | ― | 6.15% | -54.24% | |
62 Neutral | $416.31M | 11.58 | 16.04% | ― | -30.39% | 46.15% | |
61 Neutral | $314.12M | ― | -85.68% | ― | 19.68% | -13.17% | |
58 Neutral | $483.47M | ― | -25.57% | ― | -1.36% | -479.49% | |
51 Neutral | $7.95B | -0.40 | -42.50% | 2.21% | 22.29% | -1.85% | |
46 Neutral | $372.72M | ― | -102.61% | ― | 5.94% | 25.16% | |
43 Neutral | $462.96M | ― | -15.36% | ― | -0.02% | -1196.44% |
On September 5, 2025, Semler Scientific held its annual meeting of stockholders where several key proposals were voted upon. Stockholders elected William H.C. Chang as a Class I Director and approved the executive compensation on a non-binding advisory basis. They also approved an amendment to increase the authorized shares of common stock from 50 million to 210 million. However, the proposal to authorize the issuance of 42 million shares of ‘blank-check’ preferred stock was not approved. Additionally, the selection of BDO USA, P.C. as the independent registered public accounting firm for 2025 was ratified.
Semler Scientific has announced updates regarding its financial activities, including a Controlled Equity Offering℠ Sales Agreement entered on April 15, 2025, allowing the company to issue and sell up to $500 million of its common stock. By July 23, 2025, the company had raised approximately $194.3 million through this program. Additionally, Semler Scientific acquired 175 Bitcoin between July 17 and July 23, 2025, using proceeds from the ATM offering, and held a total of 5,021 Bitcoin valued at $594.8 million as of July 23, 2025. The company reported a BTC Yield of 31.3% year-to-date, indicating a strategic focus on enhancing shareholder value through Bitcoin investments.
Semler Scientific has launched a dashboard on its website to disclose information about its Bitcoin holdings, market data, and related key performance indicators. This initiative aims to ensure compliance with disclosure regulations and provide transparency to investors and stakeholders.
Semler Scientific has launched a website dashboard to disclose information about its Bitcoin holdings, market data, and key performance indicators to comply with Regulation FD. This initiative aims to provide transparent and broad distribution of material information, encouraging investors to regularly review the updates.
On June 24, 2025, Semler Scientific announced the creation of CardioVanta, Inc., a wholly-owned subsidiary dedicated to its future healthcare business activities. This strategic move aims to enhance the company’s focus on early detection of heart-related conditions and involves seeking external investment to support its initial capital requirements, potentially impacting its market positioning and stakeholder interests.
On June 22, 2025, Semler Scientific‘s board of directors approved the Fifth Amended and Restated Bylaws, effective immediately. This amendment was made to clarify compliance with Delaware General Corporation Law and to align with the company’s certificate of incorporation, potentially impacting corporate governance and operational clarity.
On June 19, 2025, Semler Scientific, Inc. announced the appointment of Joe Burnett as director of Bitcoin strategy. The company also revealed its ambitious plan to acquire 10,000 Bitcoins by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027, utilizing funds from equity and debt financings as well as cash flows from operations.